×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MGNX – macrogenics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MGNX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/10
09:00 pm
mgnx
MGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating Macrogenics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Medium
Report
MGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating Macrogenics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
12/2
04:30 pm
mgnx
MacroGenics to Participate in Upcoming Investor Conference
Medium
Report
MacroGenics to Participate in Upcoming Investor Conference
11/10
02:03 am
mgnx
MacroGenics, Inc. (NASDAQ: MGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "buy" rating.
Low
Report
MacroGenics, Inc. (NASDAQ: MGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "buy" rating.
11/7
07:12 am
mgnx
MacroGenics, Inc. (NASDAQ: MGNX) was downgraded by analysts at JMP Securities from an "outperform" rating to a "market perform" rating.
Medium
Report
MacroGenics, Inc. (NASDAQ: MGNX) was downgraded by analysts at JMP Securities from an "outperform" rating to a "market perform" rating.
11/7
06:47 am
mgnx
MacroGenics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
MacroGenics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/6
04:30 pm
mgnx
MacroGenics to Participate in Upcoming Investor Conferences
Medium
Report
MacroGenics to Participate in Upcoming Investor Conferences
11/6
08:06 am
mgnx
MacroGenics, Inc. (NASDAQ: MGNX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Low
Report
MacroGenics, Inc. (NASDAQ: MGNX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
11/5
10:32 pm
mgnx
MacroGenics (MGNX) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
MacroGenics (MGNX) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/21
04:32 pm
mgnx
Form 8-K MACROGENICS INC For: Nov 18
Low
Report
Form 8-K MACROGENICS INC For: Nov 18
11/20
10:45 am
mgnx
Form SC 13G MACROGENICS INC Filed by: Frazier Life Sciences Public Fund, L.P.
Medium
Report
Form SC 13G MACROGENICS INC Filed by: Frazier Life Sciences Public Fund, L.P.
11/14
05:13 pm
mgnx
Form SC 13G/A MACROGENICS INC Filed by: ARMISTICE CAPITAL, LLC
Medium
Report
Form SC 13G/A MACROGENICS INC Filed by: ARMISTICE CAPITAL, LLC
11/8
02:22 pm
mgnx
Form SC 13G/A MACROGENICS INC Filed by: BlackRock, Inc.
Medium
Report
Form SC 13G/A MACROGENICS INC Filed by: BlackRock, Inc.
11/5
04:04 pm
mgnx
Form 8-K MACROGENICS INC For: Nov 05
Medium
Report
Form 8-K MACROGENICS INC For: Nov 05
11/5
04:03 pm
mgnx
Form 10-Q MACROGENICS INC For: Sep 30
Low
Report
Form 10-Q MACROGENICS INC For: Sep 30
10/30
07:40 am
mgnx
Form 8-K MACROGENICS INC For: Oct 25
Low
Report
Form 8-K MACROGENICS INC For: Oct 25
10/22
03:25 pm
mgnx
Form SC 13G/A MACROGENICS INC Filed by: BlackRock, Inc.
Low
Report
Form SC 13G/A MACROGENICS INC Filed by: BlackRock, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/9
Form 4 MACROGENICS INC For: Mar 06 Filed by: Karrels James
10.7%
5/15 MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer 10.4%
12/12 MacroGenics Inc (NASDAQ: MGNX) had its "buy" rating re-affirmed by analysts at Nomura. They now have a $50.00 price target on the stock. 9.9%
3/23 Form PRE 14A MACROGENICS INC For: May 14 9.8%
4/17 Form 4 MACROGENICS INC For: Apr 16 Filed by: Risser Eric Blasius 8.5%
3/26 MacroGenics Inc (NASDAQ: MGNX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.25 price target on the stock. 7.9%
11/21 MacroGenics Inc (NASDAQ: MGNX) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating. 7.9%
2/25 MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 7.7%
1/13 MacroGenics to Present at the J.P. Morgan Healthcare Conference 7.2%
12/11 MacroGenics down 3% on uncertainty of margetuximab survival benefit [Seeking Alpha] 6.6%
5/15 MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer 10.4%
12/12 MacroGenics Inc (NASDAQ: MGNX) had its "buy" rating re-affirmed by analysts at Nomura. They now have a $50.00 price target on the stock. 9.9%
3/23 Form PRE 14A MACROGENICS INC For: May 14 9.8%
4/17 Form 4 MACROGENICS INC For: Apr 16 Filed by: Risser Eric Blasius 8.5%
3/26 MacroGenics Inc (NASDAQ: MGNX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.25 price target on the stock. 7.9%
11/21 MacroGenics Inc (NASDAQ: MGNX) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating. 7.9%
2/25 MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 7.7%
1/13 MacroGenics to Present at the J.P. Morgan Healthcare Conference 7.2%
12/11 MacroGenics down 3% on uncertainty of margetuximab survival benefit [Seeking Alpha] 6.6%
TOP News Decliners
3/13
Form 4 MACROGENICS INC For: Mar 11 Filed by: Koenig Scott
-20.5%
6/3 MacroGenics: Updating The Investment Thesis [Seeking Alpha] -17.1%
2/27 MacroGenics to Participate in Upcoming Investor Conferences -15.7%
10/22 MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer -15.3%
2/28 MacroGenics Inc (NASDAQ: MGNX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -13.4%
3/7 MacroGenics Inc (NASDAQ: MGNX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -11.9%
3/17 Form 4 MACROGENICS INC For: Mar 13 Filed by: Risser Eric Blasius -9.1%
3/4 MacroGenics Announces Departure of Chief Medical Officer -8.5%
3/25 MacroGenics Inc (NASDAQ: MGNX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.5%
6/5 MacroGenics Inc (NASDAQ: MGNX) had its "buy" rating re-affirmed by analysts at Cowen Inc. -5.9%
6/3 MacroGenics: Updating The Investment Thesis [Seeking Alpha] -17.1%
2/27 MacroGenics to Participate in Upcoming Investor Conferences -15.7%
10/22 MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer -15.3%
2/28 MacroGenics Inc (NASDAQ: MGNX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -13.4%
3/7 MacroGenics Inc (NASDAQ: MGNX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -11.9%
3/17 Form 4 MACROGENICS INC For: Mar 13 Filed by: Risser Eric Blasius -9.1%
3/4 MacroGenics Announces Departure of Chief Medical Officer -8.5%
3/25 MacroGenics Inc (NASDAQ: MGNX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.5%
6/5 MacroGenics Inc (NASDAQ: MGNX) had its "buy" rating re-affirmed by analysts at Cowen Inc. -5.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: